89Zr-girentuximab在肾细胞癌患者中的安全性、生物分布与辐射剂量学I期研究
本I期研究纳入10例疑似透明细胞肾细胞癌(ccRCC)患者,静脉给予37 MBq(±10%)的89Zr-girentuximab(质量剂量5 mg或10 mg),评估安全性、生物分布和剂量学。结果显示无≥3级治疗相关不良事件,成像可成功区分ccRCC与非ccRCC病变,全身有效剂量为0.57±0.08 mSv/MBq。
要点
- 89Zr-girentuximab在37 MBq(±10%)给药活度下安全且耐受良好。
- 成像可区分ccRCC与非ccRCC病变,并经组织学确认。
- 全身有效剂量为0.57±0.08 mSv/MBq,肝、肾和心壁受照剂量最高。
核心结论
- 89Zr-girentuximab在给药活度和质量剂量下安全且耐受良好,并可对疑似ccRCC患者进行定量PET/CT评估。
研究设计与样本
- I期研究,纳入10例疑似透明细胞肾细胞癌(ccRCC)患者,静脉给予37 MBq(±10%)的89Zr-girentuximab,质量剂量为5 mg或10 mg。
- 安全性按NCI CTCAE(版本4.03)评估,基于给药后0.5、4、24、72和168小时采集的PET/CT图像进行生物分布和正常器官剂量学分析。
- 对组织学确诊ccRCC且PET/CT可见肿瘤摄取的患者进行肿瘤剂量学分析。
主要发现
- 10例患者按方案接受89Zr-girentuximab给药,未报告≥3级治疗相关不良事件。
- 89Zr-girentuximab成像在所有患者中成功区分ccRCC与非ccRCC病变,并经组织学数据确认。
- OLINDA/EXM 2.1剂量学分析显示,受照剂量最高的器官为肝脏(1.86±0.40 mGy/MBq)、肾脏(1.50±0.22 mGy/MBq)和心壁(1.45±0.19 mGy/MBq),全身平均有效剂量为0.57±0.08 mSv/MBq。
- 在6例组织学确诊ccRCC患者中进行肿瘤剂量学分析,中位肿瘤吸收剂量为4.03 mGy/MBq(范围1.90-11.6 mGy/MBq)。
关键数值与推荐
- 给药活度:37 MBq(±10%);质量剂量:5 mg或10 mg。
- 全身平均有效剂量:0.57±0.08 mSv/MBq。
- 肝脏剂量:1.86±0.40 mGy/MBq;肾脏剂量:1.50±0.22 mGy/MBq;心壁剂量:1.45±0.19 mGy/MBq。
- 肿瘤中位吸收剂量:4.03 mGy/MBq(范围1.90-11.6 mGy/MBq),基于6例组织学确诊ccRCC患者。
临床怎么用
- 89Zr-girentuximab PET/CT可用于疑似ccRCC患者的无创定性评估,并区分ccRCC与非ccRCC病变。
- 临床应用时需关注肝、肾和心壁的辐射剂量,全身有效剂量为0.57±0.08 mSv/MBq。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In this phase I study, we evaluated the safety, biodistribution and dosimetry of [89Zr]Zr-DFO-girentuximab (89Zr-girentuximab) PET/CT imaging in patients with suspicion of clear cell renal cell carcinoma (ccRCC). METHODS: Ten eligible patients received an intravenous administration of 37 MBq (± 10%) of 89Zr-girentuximab at mass doses of 5 mg or 10 mg. Safety was evaluated according to the NCI CTCAE (version 4.03). Biodistribution and normal organ dosimetry was performed based on PET/CT images acquired at 0.5, 4, 24, 72 and 168 h post-administration. Additionally, tumour dosimetry was performed in patients with confirmed ccRCC and visible tumour uptake on PET/CT imaging. RESULTS: 89Zr-girentuximab was administered in ten patients as per protocol. No treatment-related adverse events ≥ grade 3 were reported. 89Zr-girentuximab imaging allowed successful differentiation between ccRCC and non-ccRCC lesions in all patients, as confirmed with histological data. Dosimetry analysis using OLINDA/EXM 2.1 showed that the organs receiving the highest doses (mean ± SD) were the liver (1.86 ± 0.40 mGy/MBq), the kidneys (1.50 ± 0.22 mGy/MBq) and the heart wall (1.45 ± 0.19 mGy/MBq), with a mean whole body effective dose of 0.57 ± 0.08 mSv/MBq. Tumour dosimetry was performed in the 6 patients with histologically confirmed ccRCC resulting in a median tumour-absorbed dose of 4.03 mGy/MBq (range 1.90-11.6 mGy/MBq). CONCLUSIONS: This study demonstrates that 89Zr-girentuximab is safe and well tolerated for the administered activities and mass doses and allows quantitative assessment of 89Zr-girentuximab PET/CT imaging in patients with suspicion of ccRCC. TRIAL REGISTRATION: NCT03556046-14th of June, 2018.
引用
- Merkx RIJ, Lobeek D, Konijnenberg M, et al. Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021. PMID: 33651116. doi:10.1007/s00259-021-05271-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。